ResMed Inc. (RMD) Stock Price & How to Invest

Last updated November 2026

Short answer

ResMed (RMD) is a San Diego based maker of CPAP and bilevel devices for sleep apnea, the masks that attach to them, and the software that runs the home medical equipment suppliers who distribute both. A screener line reading "Medical Instruments, ~$33.5B cap, ~5.9x sales" implies capital equipment, and that is the structural thing it gets wrong: of the $5.65 billion ResMed booked in fiscal 2026 (the year ended June 30, 2026), devices were ~$2.89 billion, masks and other consumables ~$2.09 billion, and Residential Care Software ~$676 million. Close to half the company is recurring resupply and subscription revenue riding on an installed base of roughly 35 million cloud connected devices. At $238.24 on November 20, 2026, the stock is down ~2.3% over a year and ~2.7% year to date, even after a fiscal first quarter that beat EPS estimates by $0.24, for two reasons a valuation multiple will not tell you: a Class 1 FDA recall on the Astral ventilator line, and an unsettled argument about what GLP-1 weight loss drugs do to the long run sleep apnea patient pool.

RMD stock price

As of 2026-11-20, ResMed Inc. (RMD) last closed at $235.63, down 6.0% over the past year. Over the past 52 weeks it has traded between $182.82 and $275.96.

RMD last close
$235.63
1 day
-0.53%
1 month
-4.29%
1 year
-6.03%
52-week range
$182.82 to $275.96
Last close
2026-11-20

Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or ResMed Inc.'s investor relations page. Walnut is informational, not investment advice.

RMD key stats

At $235.63 on November 20, 2026, ResMed Inc. (RMD) has a market cap of $33.1B, a P/E of 21.5 on trailing earnings (17.8 on forward earnings) and a dividend yield of 1.12%. It next reports earnings around January 28, 2027 (estimated).

Market cap
$33.1B
P/E (trailing)
21.5
P/E (forward)
17.8
EPS (trailing 12 months)
$10.98
Price to book
5.6
Dividend yield
1.12%
Beta
0.76
Next earnings
around January 28, 2027 (estimated)

Market cap, P/E and yield are measured at the $235.63 price on November 20, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.

What's new with ResMed Inc. (RMD)?

The last two weeks for ResMed Inc., as of November 22, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.

  • RMD closed at $235.63 on November 20, 2026, down 1.6% over the past five trading days (from $239.53).
  • ResMed Inc. next reports quarterly results around January 28, 2027 (estimated).
  • On November 19, 2026, ResMed Inc. filed an 8-K with the SEC reporting a change in its directors or officers and the results of a shareholder vote (Item 5.02, Item 5.07). Read the 8-K on sec.gov

Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.

ResMed Inc. (RMD) latest quarter

ResMed reported revenue of $1.4 billion for Q1 fiscal 2027, up 6% from a year earlier (ResMed, Oct 29, 2026).

Revenue
$1.4 billion
up 6% from a year earlier
Diluted EPS (GAAP)
$2.92
up 23% from a year earlier
Sleep and Breathing Health
$1.3 billion
up 8% from a year earlier

Source: ResMed Q1 fiscal 2027 results, Oct 29, 2026. Full earnings breakdown

What does ResMed Inc. (RMD) do?

ResMed sells the equipment and software used to treat sleep apnea, chronic obstructive pulmonary disease and other respiratory conditions outside the hospital. The hardware side splits into flow generators (the AirSense and AirCurve device families, plus the Astral and Stellar life support ventilators) and the masks, cushions, tubing and filters patients replace on a rolling schedule. In fiscal 2026, the year ended June 30, 2026, Americas devices produced ~$1.77 billion and Americas masks and other ~$1.51 billion, while the rest of the world contributed ~$1.12 billion in devices and ~$572 million in masks. A third line, Residential Care Software, brought in ~$676 million from Brightree, MEDIFOX DAN and MatrixCare, the back office systems that home medical equipment dealers, out of hospital care providers and skilled nursing operators use for billing, resupply and scheduling. Roughly 11,370 employees support ~35 million cloud connected devices and ~37 million patients registered in AirView, the remote monitoring platform. Manufacturing is concentrated in Singapore, Sydney and Tijuana. The company is incorporated in Delaware, reports in US dollars, lists on the NYSE, and also trades in Australia as CHESS Depositary Interests.

The economics look less like a device maker than the sector label suggests. Gross margin reached 61.1% on a GAAP basis in fiscal 2026 and 62.4% non-GAAP, up 240 basis points year on year, helped by manufacturing efficiency and a mix shift toward masks. Operating margin was 33.4% GAAP, net income $1.52 billion, and diluted EPS $10.43 GAAP against $11.17 non-GAAP. Free cash flow came in at ~$1.65 billion on ~$1.81 billion of operating cash flow, which funded $700 million of buybacks and $350 million of dividends. The balance sheet carries ~$1.47 billion of cash against ~$659 million of debt, so at fiscal year end the enterprise value sat slightly below the equity market capitalisation. What investors are actually paying for is the annuity: a patient set up on a device replaces cushions and masks for years, and Brightree sits inside the resupply workflow that triggers those reorders. What they are discounting is the pair of open questions on the tape: the Astral field safety action and GLP-1 substitution. Management guided fiscal 2027 to $5.75 billion to $5.85 billion of revenue and $12.00 to $12.25 of non-GAAP EPS, both after absorbing the Astral hit and the MatrixCare sale. The first quarter of that year, reported in late October, came in at ~$1.41 billion of revenue, up ~5.9% from a year earlier and slightly above the ~$1.39 billion consensus, with GAAP net income of ~$418 million and non-GAAP EPS of $2.91 against ~$2.67 expected. Trailing twelve month revenue is now ~$5.73 billion and net income ~$1.59 billion. The shares closed at $238.24 on November 20, 2026, giving a market capitalisation of ~$33.5 billion. That is ~2.7% lower for the year to date, ~2.3% lower than a year earlier and ~5.8% lower over the past month, roughly flat over three months, and well above the summer low near the $180.27 bottom of its 52 week range. The next report, for the December quarter, is estimated for around January 28, 2027, with consensus near $2.99 of EPS on ~$1.46 billion of revenue.

What's driving ResMed Inc. (RMD)?

1. Resupply, not new device placements, carries the growth

Masks and other consumables grew 10% in the Americas and 12% internationally on a constant currency basis in the June 2026 quarter, faster than device revenue in both regions. That matters because a mask sale is repeatable and higher margin, while a flow generator is a one time placement every five years or so. The installed base of ~35 million connected devices is the denominator, and Brightree's resupply automation is what converts it into orders. ResMed reports ~37 million patients in AirView, a figure that only moves in one direction as long as new setups exceed attrition. Gross margin expansion of 240 basis points non-GAAP in fiscal 2026 came substantially from this mix shift.

2. The Astral recall is a sized, dated hole rather than an open ended one

ResMed issued a global medical device correction for Astral 100 and Astral 150 ventilators built before October 2024, covering 168,069 units, after finding that an internal supercapacitor can leak electrolyte, damage the circuit board and push the device into a fail safe state that stops ventilation. The FDA classified it Class 1 (recall number Z-2735-2026, initiated June 25, 2026, posted July 28), with five serious injuries and no deaths reported as of June 23, 2026. Management took a $42 million provision in the fourth quarter, suspended new Astral sales while prioritising the most severe patients, and guided to roughly $75 million of lost fiscal 2027 revenue. Against $5.65 billion of fiscal 2026 sales, that is about 1.3 points of growth.

3. Software is being pruned, not scaled

Residential Care Software grew only 4% in constant currency in fiscal 2026, the slowest of the three revenue lines. In July 2026 ResMed agreed to sell MatrixCare, the skilled nursing and out of hospital care platform, to Frazier Healthcare Partners for $490 million, with the deal expected to close in the first quarter of fiscal 2027 and $457 million already sitting in assets held for sale at June 30, 2026. The retained software assets, Brightree and MEDIFOX DAN, sit much closer to the device and resupply flow. The divestiture shrinks reported revenue and removes the slowest growing piece, so fiscal 2027 comparisons need to be read on a core, constant currency basis.

4. ResMed's own GLP-1 data cuts against the short thesis

The bear case since Eli Lilly's Zepbound was cleared for obstructive sleep apnea has been that weight loss drugs shrink the addressable patient pool. ResMed's response is a study of 2.5 million patients showing that people prescribed a GLP-1 were 1,070 basis points more likely to start PAP therapy than a matched non-GLP-1 cohort, with better resupply rates at one and three years after setup. The mechanism is plausible: a patient engaged enough with their weight to fill a GLP-1 prescription is a patient more likely to seek a sleep diagnosis. Short interest stood at ~10.9% of shares outstanding in August 2026, which is unusually high for a large cap medtech and shows the market has not accepted the argument.

5. The first fiscal 2027 quarter cleared a low bar

ResMed reported its first quarter of fiscal 2027 (the September 2026 quarter) in late October. Consensus had sat at ~$2.67 of EPS on ~$1.39 billion of revenue, pencilling in only ~4.6% EPS growth against $2.55 a year earlier, a low bar set by the Astral sales suspension and the MatrixCare divestiture. The company delivered ~$1.41 billion of revenue, up ~5.9%, and $2.91 of non-GAAP EPS, a $0.24 beat and its fifth straight, after beats of $0.05 to $0.09 in the four quarters before. GAAP net income was ~$418 million, the highest of the last four quarters. The stock did not rerate on it: it closed at $238.24 on November 20, 2026, ~5.8% lower over the month. The 17 analysts tracked carry a mean target near $264, about 11% above that close, and expect ~$2.99 of EPS on ~$1.46 billion of revenue for the December quarter, due around January 28, 2027.

What are the risks to ResMed Inc. (RMD)?

Philips is the single largest competitive variable. Its Respironics business exited most of the US new device market after the 2021 foam recall and the subsequent consent decree, handing ResMed several points of share it did not have to compete for. Any credible return of Philips capacity to the US sleep market would meet a ResMed that has been pricing and allocating capital against a diminished rival for five years, and mask share, where switching costs are lowest, would be the first place to show it. The GLP-1 question is genuinely open. ResMed's 2.5 million patient study is observational and self published, and it measures behaviour in the early years of drug adoption rather than the steady state after sustained weight loss; a cohort that loses enough weight to fall below the diagnostic threshold would leave the resupply base entirely. Quality systems are the second live risk. A Class 1 designation on 168,069 Astral units invites FDA scrutiny that can extend past the specific defect into inspection findings, warning letters or a consent decree, and Philips is the cautionary case for how far that can go. Reimbursement adds pressure from the other side: most US revenue passes through home medical equipment suppliers paid by Medicare and commercial plans, so competitive bidding rounds and prior authorisation tightening compress the distributor before they reach ResMed. Manufacturing is concentrated in Singapore, Sydney and Tijuana, which leaves the gross margin exposed to tariffs and freight. Roughly a third of revenue is non-US, so a stronger dollar reduces reported growth. Finally, short interest near 10.9% in August and a 52 week range of $180.27 to $277.67, with the stock ~2.3% lower over a year even as trailing GAAP earnings grew to ~$1.59 billion and quarterly earnings rose ~23% year on year, mean sentiment, not fundamentals, has been setting the price. Revenue growth of ~5.9% in the September quarter, down from 9% in June, is the number the GLP-1 bears will point to until the Astral and MatrixCare effects lap.

What is the ResMed Inc. (RMD) forecast?

17 analysts publish price targets on RMD, averaging $264.33 as of November 2026, or +12.2% against the $235.63 share price on November 20, 2026. The published targets run from $210.00 to $320.00, a moderate spread, and the ratings split 9 buy, 10 hold, 1 sell. Over the last six months there have been 7 raises and 4 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full RMD forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

Is RMD a buy or a sell?

We give no verdict on ResMed Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Resupply, not new device placements, carries the growth. Masks and other consumables grew 10% in the Americas and 12% internationally on a constant currency basis in the June 2026 quarter, faster than device revenue in both regions. The most optimistic published target, $320.00, assumes this works close to its best case.

The case against. Philips is the single largest competitive variable. The most pessimistic target, $210.00, is roughly what RMD is worth if this bites instead.

Read the full bull and bear case on RMD, including what would have to change to break either one. Walnut is not an investment adviser.

Has ResMed Inc. (RMD) split its stock?

No. ResMed Inc. (RMD) has not split its stock in the last 10 years. The statement covers only the window we check, so an older split in the company’s history is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.

How is ResMed Inc. (RMD) valued?

Market cap, P/E and dividend yield at today's price are in the RMD key stats above. The business figures below come from ResMed Inc.'s reported results as of November 2026 and change when it next reports.

  • Revenue (trailing twelve months and fiscal 2026): ~$5.73 billion for the twelve months to September 30, 2026. Fiscal 2026, the twelve months ended June 30, 2026, brought ~$5.65 billion, up ~10% reported and ~8% in constant currency from ~$5.15 billion in fiscal 2025, ~$4.69 billion in fiscal 2024 and ~$4.22 billion in fiscal 2023. The September 2026 quarter, the first of fiscal 2027, produced ~$1.41 billion, up ~5.9% year on year and slightly above the ~$1.39 billion consensus, after the Astral sales suspension and the MatrixCare divestiture.
  • Earnings and margins: Trailing twelve month GAAP net income of ~$1.59 billion and trailing GAAP EPS of ~$10.98, on a ~61.8% gross margin, ~34.0% operating margin and ~27.8% net margin. September 2026 quarter GAAP net income was ~$418 million, up ~23% year on year, and non-GAAP EPS was $2.91 against ~$2.67 expected. For fiscal 2026, GAAP diluted EPS was $10.43 and non-GAAP $11.17, up 17%, with GAAP gross margin of 61.1% and non-GAAP 62.4%; the fourth quarter carried a $42 million Astral provision.
  • Revenue mix (the line a screener misses): Fiscal 2026 devices totalled ~$2.89 billion (~$1.77 billion Americas, ~$1.12 billion rest of world), masks and other consumables ~$2.09 billion (~$1.51 billion Americas, ~$572 million rest of world), and Residential Care Software ~$676 million. Sleep and Breathing Health was ~$4.98 billion of the total. Masks grew 10% in the Americas and 12% internationally in the fourth quarter on a constant currency basis, against ~4% constant currency growth for software across the year.
  • Cash flow and balance sheet: Trailing operating cash flow of ~$1.77 billion and free cash flow of ~$1.30 billion, per Yahoo Finance, against ~$1.81 billion and ~$1.65 billion for fiscal 2026. Cash of ~$1.01 billion against ~$611 million of total debt at September 30, 2026, a net cash position and a debt to equity ratio near 0.10. Cash was ~$1.47 billion at June 30, 2026, when ~$457 million of assets were held for sale for the pending MatrixCare disposal.
  • Capital returns: ResMed returned more than $1 billion to shareholders in fiscal 2026, roughly 70% more than the prior year: ~$700 million of buybacks and ~$350 million of dividends. The quarterly dividend was raised 10% to $0.66 per share in August 2026, an annualised $2.64 and a yield near 1.1% at the November 20 close of $238.24, on a payout ratio around 22% of trailing GAAP earnings. Management guided to more than $1.85 billion of combined buybacks and dividends in fiscal 2027.
  • Market pricing: Shares closed at $238.24 on November 20, 2026, inside a 52 week range of $180.27 to $277.67: down ~5.8% over one month, up ~0.7% over three, down ~2.7% year to date and ~2.3% over twelve months. Market capitalisation is ~$33.5 billion. That works out to ~21.7x trailing GAAP EPS of ~$10.98, ~18.0x forward EPS of ~$13.23, ~5.9x sales and ~15.5x EV/EBITDA. The 17 analysts tracked rate it a buy on average, with a mean target near $264.
  • Next report (fiscal Q2 2027): Estimated for around January 28, 2027. Consensus calls for EPS of ~$2.99 on revenue of ~$1.46 billion, about 6.4% EPS growth. For the full fiscal year to June 2027, analysts average ~$12.14 of EPS on ~$5.83 billion of revenue, inside management's guidance; fiscal 2028 estimates sit near $13.23 and ~$6.21 billion. The last five quarters all beat EPS consensus: $2.55 vs $2.50, $2.81 vs $2.72, $2.86 vs $2.80, $2.95 vs $2.89 and $2.91 vs $2.67.

As of November 2026: At ~$238 the stock trades near 21.7x trailing GAAP earnings and ~18x forward estimates, below the ~30x it commanded before the GLP-1 debate began. Fiscal 2027 guidance of $5.75 billion to $5.85 billion of revenue and $12.00 to $12.25 of non-GAAP EPS absorbs the ~$75 million Astral headwind and the MatrixCare sale, and the first quarter's $2.91 of non-GAAP EPS puts the year on pace for the upper half of that range if it repeats, while revenue growth of ~5.9% sits inside the 5% to 7% core guide. Mature medtech multiple, double digit EPS growth target: that is the valuation argument in one line.

Who competes with ResMed Inc. (RMD)?

Sleep and respiratory device makers

Philips, through Respironics, was historically the co-leader and remains the defining competitive variable after its 2021 foam recall and subsequent US consent decree pulled it back from new device sales. Fisher & Paykel Healthcare of New Zealand competes hardest in masks and humidification and has been taking incremental share. React Health (which acquired the 3B Medical line) and Germany's Lowenstein Medical serve the value end of the flow generator market, particularly where competitive bidding compresses supplier reimbursement. In life support ventilation, where the Astral line sits, Vyaire, Hamilton Medical and Breas compete for the home and portable segments. ResMed's advantage is less the hardware than the AirView data layer and the resupply workflow that sits on top of it.

Alternative sleep apnea therapies

Inspire Medical Systems sells an implanted hypoglossal nerve stimulator for patients who cannot tolerate PAP, and its growth has been the clearest evidence that a share of the mask averse population will pay for an alternative. Nyxoah is pursuing the same indication with the Genio system. Vivos Therapeutics and a large fragmented set of dental sleep providers offer oral appliances for milder cases. Pharmacology is the newest entrant: Eli Lilly's Zepbound carries an obstructive sleep apnea indication tied to weight loss, and Novo Nordisk's portfolio addresses the same underlying obesity driver. ResMed argues these expand diagnosis rather than replace therapy, and its own data on GLP-1 patients supports that, but the substitution debate is what the short interest is expressing.

Out of hospital care software

The Residential Care Software line competes against PointClickCare and Netsmart in skilled nursing and post acute records, WellSky across home health and durable medical equipment workflows, and a long tail of regional billing vendors. This is where the segment's ~4% constant currency growth came from, and the pending $490 million sale of MatrixCare to Frazier Healthcare Partners narrows ResMed's exposure to it. What remains, Brightree in home medical equipment and MEDIFOX DAN in German outpatient care, sits directly adjacent to the device business rather than competing as a standalone health IT vendor.

What stocks are similar to ResMed Inc. (RMD)?

Other names that sit close to RMD: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. They are useful if you want to spread one thesis across several tickers.

How to invest in ResMed Inc. (RMD)

There are three common ways to get RMD exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so RMD sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where RMD fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

The bottom line on ResMed Inc. (RMD)

As of November 20, 2026, ResMed is a high margin, cash generative franchise at ~21.7x trailing GAAP earnings and ~18x forward estimates, a discount to its own multi-year history. The gap reflects a known ~$75 million Astral revenue hole in fiscal 2027 and an unresolved GLP-1 debate, against a business that grew revenue 10% to ~$5.65 billion last year and has beaten EPS consensus in each of the last five quarters. The fiscal first quarter (the September 2026 quarter) delivered ~$1.41 billion of revenue, up ~5.9%, and $2.91 of non-GAAP EPS against ~$2.67 expected, so the Astral and MatrixCare gaps showed up in revenue growth more than in earnings.

More on ResMed Inc. (RMD)

Whether RMD is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is RMD a buy or a sell?, and where the stock could go from here in the RMD stock forecast.

For income investors, whether RMD pays a dividend and how the payout looks is covered in does RMD pay a dividend? And to weigh RMD against a peer, read the full side-by-side comparisons: RMD vs LLY and RMD vs NVO.

Wondering how RMD fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about ResMed Inc.

Ask Walnut's AI anything about RMD and see how it fits what you own.

FAQ

What does ResMed do?

+

ResMed makes the equipment used to treat sleep apnea and chronic respiratory disease at home, and the software that supports the businesses distributing it. The core products are CPAP and bilevel flow generators (the AirSense and AirCurve families), the masks and cushions patients wear with them, and the Astral and Stellar life support ventilators. A third business, Residential Care Software, sells back office systems to home medical equipment dealers and out of hospital care providers. In fiscal 2026, the year ended June 30, 2026, devices generated ~$2.89 billion, masks and other consumables ~$2.09 billion and software ~$676 million of $5.65 billion in total revenue. Roughly 35 million devices are cloud connected and ~37 million patients are registered in the AirView monitoring platform.

Why did ResMed stock drop?

+

Shares fell about 6% after hours on the fiscal fourth quarter release of August 6, 2026, and as of November 20, 2026 they are ~2.3% lower than a year earlier at $238.24, after a rebound off the summer low near $180.27 and a ~5.8% slip over the past month. Two things drove the August drop. ResMed guided to roughly $75 million of lost fiscal 2027 revenue from a field safety action on its Astral ventilators, having taken a $42 million provision in the quarter and suspended new Astral sales. Quarterly revenue of ~$1.46 billion also came in fractionally below the ~$1.47 billion consensus, even though non-GAAP EPS of $2.95 beat the ~$2.89 expected. Underneath both sits a longer running argument about whether GLP-1 weight loss drugs shrink the sleep apnea patient pool, which has kept short interest near 10.9% of shares. The September quarter, a $0.24 EPS beat on ~5.9% revenue growth, did not change that debate.

Are GLP-1 drugs like Zepbound a threat to ResMed?

+

The bear argument holds that drugs treating obesity remove the underlying cause of obstructive sleep apnea, particularly since Eli Lilly's Zepbound gained an OSA indication. ResMed's counter is empirical. It studied 2.5 million patients and found that those prescribed a GLP-1 were 1,070 basis points more likely to begin PAP therapy than a matched cohort, with higher mask resupply rates at both one and three years after setup. The proposed mechanism is engagement: someone treating their weight is more likely to pursue a sleep diagnosis. The study is observational and covers the early adoption period rather than a steady state, so it does not settle the question. The market has not accepted it either, which is what the elevated short interest and compressed multiple reflect.

Is ResMed a good dividend stock?

+

ResMed pays a dividend but is not primarily an income holding. The quarterly payment was raised 10% to $0.66 per share in August 2026, an annualised $2.64, which works out to a yield near 1.1% at the November 20, 2026 close of $238.24. The payout ratio is roughly 22% of trailing GAAP earnings, so the dividend is well covered by ~$1.65 billion of fiscal 2026 free cash flow, and the low ratio leaves considerable room to keep raising it. Buybacks are the larger channel: ResMed spent ~$700 million repurchasing shares in fiscal 2026 versus ~$350 million on dividends, and guided to more than $1.85 billion of combined returns in fiscal 2027. Anyone screening on yield alone would pass over it; the case, if there is one, rests on growth in the payment rather than its current size.

Who are ResMed's competitors?

+

In sleep and respiratory devices the historical co-leader is Philips through Respironics, which stepped back from the US new device market after its 2021 foam recall and consent decree. Fisher & Paykel Healthcare competes directly in masks and humidification, while React Health and Lowenstein Medical serve the value end. In alternative therapies, Inspire Medical Systems sells an implanted hypoglossal nerve stimulator and Nyxoah is pursuing the same indication, with oral appliance makers such as Vivos Therapeutics covering milder cases. Eli Lilly and Novo Nordisk represent the pharmacological path through weight loss. On the software side, Brightree and MEDIFOX DAN compete with WellSky, PointClickCare and Netsmart. ResMed's structural advantage is the AirView data layer and the automated resupply workflow, which are harder to replicate than the hardware.

What happened with the ResMed Astral ventilator recall?

+

ResMed issued a global medical device correction for Astral 100 and Astral 150 ventilators manufactured before October 2024. An internal supercapacitor can leak electrolyte over time, damage the printed circuit board and force the ventilator into a fail safe state, which stops ventilation if it happens during therapy. The FDA gave it a Class 1 designation, the most serious category, under recall number Z-2735-2026, initiated June 25, 2026 and posted July 28. The record covers 168,069 devices globally, distributed across 49 US states, the District of Columbia and Puerto Rico, with five serious injuries and no deaths reported as of June 23, 2026. Patients were told not to stop using the devices without clinician instruction. ResMed took a $42 million provision, suspended new Astral sales, and expects roughly $75 million of revenue impact in fiscal 2027.

Is ResMed profitable and how much cash does it generate?

+

Yes, and by a wide margin. Fiscal 2026 produced ~$1.52 billion of GAAP net income on ~$5.65 billion of revenue, a 27% net margin, with GAAP gross margin of 61.1% and operating margin of 33.4%. Non-GAAP diluted EPS of $11.17 rose 17% year on year. Operating cash flow was ~$1.81 billion and free cash flow ~$1.65 billion, funding ~$700 million of buybacks and ~$350 million of dividends with room left over. The balance sheet holds ~$1.47 billion of cash against ~$659 million of total debt, so ResMed carries net cash and its enterprise value sits below its market capitalisation, ~$33.5 billion as of November 20, 2026. Return on equity ran ~24% and return on invested capital ~26%. Over the twelve months to September 2026, GAAP net income rose to ~$1.59 billion on ~$5.73 billion of revenue.

Why is ResMed's fiscal year different and what is the fiscal 2027 guidance?

+

ResMed's fiscal year ends June 30, so what most data providers label "fiscal 2026" covers July 1, 2025 through June 30, 2026, and its fourth quarter is the April to June period reported in early August. Getting this right matters when comparing it to calendar year peers. For fiscal 2027, the year ending June 30, 2027, management guided to revenue of $5.75 billion to $5.85 billion with core constant currency growth of 5% to 7%, and non-GAAP diluted EPS of $12.00 to $12.25, up 12% to 14%. Both absorb roughly $75 million of lost Astral revenue and the pending sale of MatrixCare to Frazier Healthcare Partners for $490 million, which was expected to close in the first fiscal quarter. The first quarter itself brought ~$1.41 billion of revenue, up ~5.9%, and $2.91 of non-GAAP EPS. ResMed reports in US dollars, lists on the NYSE, and also trades in Australia as CHESS Depositary Interests.

How has RMD stock performed in 2026?

+

As of November 20, 2026, ResMed closed at $238.24, down ~2.7% for the year to date and ~2.3% over twelve months. The path was uneven: the stock slid toward the $180.27 low of its 52 week range as the Astral recall and GLP-1 worries weighed, rallied into October, then eased ~5.8% over the past month despite a fiscal first quarter EPS beat. The 52 week high is $277.67. At the current price the market capitalisation is ~$33.5 billion, the trailing P/E ~21.7 and the forward P/E ~18. Walnut is not an investment adviser, and past moves say nothing certain about future ones.

When does ResMed report earnings next?

+

ResMed's second quarter of fiscal 2027, covering October to December 2026, is estimated to be reported around January 28, 2027. Analysts expect EPS of ~$2.99 on revenue of ~$1.46 billion, about 6.4% EPS growth. The modest expected growth reflects the suspended Astral sales and the divested MatrixCare business. ResMed has topped the EPS consensus in each of its last five quarters, most recently $2.91 against ~$2.67 in the September 2026 quarter.

How did ResMed do in its latest quarter?

+

In the first quarter of fiscal 2027, the three months ended September 30, 2026, ResMed reported revenue of ~$1.41 billion, up ~5.9% from ~$1.34 billion a year earlier and slightly above the ~$1.39 billion consensus. GAAP net income was ~$418 million, up ~23% year on year, and non-GAAP EPS of $2.91 beat the ~$2.67 estimate by $0.24, its largest beat in the last five quarters. Revenue growth slowed from 9% in the June quarter as the Astral sales suspension and the MatrixCare sale took effect, while earnings kept growing faster than sales.

Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with ResMed Inc.'s investor relations page or your broker before making investment decisions.